



Complete molar pregnancy in adolescents from North and South America: Clinical presentation and risk of gestational trophoblastic neoplasia



Renan Rocha Soares ^a, Izildinha Maestá ^{a,b,*}, José Colón ^c, Antonio Braga ^{d,e}, Aleydah Salazar ^f, Rafael Cortés Charry ^f, Sue Yazaki Sun ^g, Donald P. Goldstein ^{h,i}, Ross S. Berkowitz ^{h,i}

^a Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP-Sao Paulo State University, Botucatu, SP, Brazil

^b Trophoblastic Diseases Center of the Botucatu Medical School, UNESP-Sao Paulo State University, Botucatu, SP, Brazil

^c Maternidad Concepción Palacios de Caracas, Venezuela

^d Trophoblastic Disease Center of Maternity School of Rio de Janeiro Federal University, Rio de Janeiro, Brazil

^e Trophoblastic Disease Center of Antonio Pedro University Hospital of Fluminense Federal University, Rio de Janeiro, Brazil

^f Department of Obstetrics and Gynecology, GTD Unit, University Hospital of Caracas, Central University of Venezuela, Caracas, Venezuela

^g Trophoblastic Disease Center of São Paulo Hospital, Department of Obstetrics, Paulista School of Medicine, UNIFESP-São Paulo Federal University, São Paulo, SP, Brazil

^h New England Trophoblastic Disease Center, Donald P. Goldstein, MD Trophoblastic Tumor Registry, Brigham and Women's Hospital, Harvard Cancer Center/Dana Farber Cancer Institute, Boston, MA, USA

ⁱ Harvard Medical School, Boston, USA

HIGHLIGHTS

- A larger percentage of patients with molar pregnancy are adolescents in South America (31%) than in North American (13%).
- CHM complications and GTN risk factors are more frequent in South American than in North American adolescents.
- The percentage of adolescents treated for postmolar GTN did not differ between South American and North American sites.

ARTICLE INFO

Article history:

Received 13 May 2016

Received in revised form 18 June 2016

Accepted 1 July 2016

Available online 8 August 2016

Keywords:

Molar pregnancy

Adolescents

Gestational trophoblastic neoplasia

ABSTRACT

Objectives. To compare complete hydatidiform mole (CHM) clinical presentation and risk factors associated with GTN development between North American and South American adolescents.

Methods. This non-concurrent cohort study was undertaken including adolescents with CHM referred to centers in North America (New England Trophoblastic Disease Center, Harvard University, USA), and South America (Botucatu Trophoblastic Disease Center-São Paulo State University, Brazil; Trophoblastic Unit of Central University of Venezuela and Maternidad Concepción Palacios of Caracas, Venezuela) between 1990 and 2012. Data were obtained from medical records and pathology reports. Study participants were allocated into 2 groups: North America (NA) and South America (SA).

Results. In NA and SA, 13.1% and 30.9% of patients with hydatidiform mole were adolescents, respectively. Of these, 77.6% in NA and 86.1% in SA had pathologic diagnosis of CHM ($p = 0.121$). Vaginal bleeding (SA = 69% vs NA = 51%; $p = 0.020$), anemia (SA = 48% vs NA = 18%; $p < 0.001$), and elevated serum hCG (SA = 232,860 mIU/mL vs NA = 136,412 mIU/mL; $p = 0.039$) were more frequent in SA than in NA. Median gestational age at diagnosis (SA = 12 weeks, NA = 11 weeks; $p = 0.030$) differed whereas GTN development rate (SA = 20%, NA = 27%; $p = 0.282$) showed no significant difference between groups. Compared to NA, medical complications and clinical factors associated with post-molar GTN were more frequent among SA adolescents.

Conclusions. Medical complications and clinical factors associated with GTN development were more frequent in SA than in NA adolescents with CHM, suggesting that, in South America, awareness about the importance of diagnosing molar pregnancy early and considering CHM in the differential diagnosis in adolescents suspected to be pregnant should be raised.

© 2016 Elsevier Inc. All rights reserved.

* Corresponding author at: Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP-Sao Paulo State University, Botucatu, SP, Brazil.
E-mail address: imaesta@fmb.unesp.br (I. Maestá).

1. Introduction

Hydatidiform mole (HM), or molar pregnancy, is an uncommon pathologic gestation characterized by abnormal development of both embryonic and extraembryonic tissues. Based on histopathology, clinical features, and chromosomal patterns, HM is characterized as either complete mole (CHM) or partial mole (PHM).

Maternal age has been reported as a significant risk factor for molar pregnancy across many countries including the United States, Asia, Europe and the Middle East [1,2]. Women < 16 or > 40 years of age have a 4–10 times higher risk of developing a hydatidiform mole (HM) than those aged 20–30 [3–5]. In the U. K., the overall risk for women of reproductive age is < 1: 500 [1]. However, risks are slightly higher for younger women (1:378–563 for teenagers aged 14–17), and significantly increased for those aged > 40 (1:423 at 40, 1:101 at 45). At the extremes of the reproductive age range, the risk of HM for girls pregnant at the age of 13 is 1:208, and 1:8 for women aged \geq 50 [1].

Although advanced maternal age is associated with a higher risk for molar pregnancy, HM patients > 40 years represent 4.5–5% [4,6], whereas adolescents with HM account for 10–34% of the cases in large trophoblastic diseases referral centers [5,7–9].

Adolescence has also been associated with increased risk of complete mole (CHM) [2,3,5], which increases the risk of developing postmolar gestational trophoblastic neoplasia (GTN) and, hence, the need for chemotherapy [10,11]. Studies assessing the risk of developing malignancy in adolescents have yielded conflicting results [5,12,13]; while some have reported increased risks [12], others have described a better prognosis for HM in this age group [5,13].

The clinical factors associated with risk of gestational trophoblastic neoplasia after CHM [14,15] remain uninvestigated in adolescents. Moreover, studies evaluating the different biological features and socio-economic development levels found in different countries and regions are still lacking.

Therefore, this study was undertaken to assess and compare CHM clinical presentation and risk for gestational trophoblastic neoplasia in adolescents from a center in North America with centers in South America in order to investigate potential differences and their influence on GTN outcome.

2. Methods

This retrospective study included adolescents with complete hydatidiform mole (CHM) who were allocated into two nonconcurrent cohorts: North America - consisting of adolescents attending the New England Trophoblastic Disease Center (Brigham and Women's Hospital, USA); and South America (SA) - including adolescents treated in the Botucatu Trophoblastic Disease Center of São Paulo State University-Unesp (Brazil), the Trophoblastic Unit of the Central University of Venezuela, and the Maternidad Concepcion Palacios of Caracas (Venezuela), from 1990 to 2012. Adolescence was defined according to the definition of the World Health Organization as 10–19 years of age [16]. CHM was diagnosed based on classical histopathologic findings using the same criteria [17] in all centers.

The following data were collected by review of medical records: maternal age, gestational age at diagnosis, uterine size, pre-evacuation human chorionic gonadotropin (hCG) level, presence of theca lutein cysts > 6 cm, anemia (hemoglobin < 11 g/dL), vaginal bleeding, pre-eclampsia and hyperemesis. Gestational age was calculated on the basis of the date of the last menstrual period. Uterine size was considered excessive when the uterus was at least 4 weeks greater in size than expected for gestational age on clinical examination [15,18]. Theca lutein ovarian cysts > 6 cm were identified by pelvic ultrasound and bimanual pelvic examination under anesthesia prior to uterine evacuation [15]. Vaginal bleeding was defined as any bleeding either reported by the patient or detected during pelvic examination. Pre-eclampsia was determined as the presence of blood pressure \geq 140/

90 mm Hg with proteinuria [19]. Hyperemesis was defined as five or more episodes of nausea and vomiting per day requiring the use of antiemetics.

Serum hCG levels were measured before evacuation and every 1–2 weeks after evacuation for postmolar follow up [15]. According to the 2002 FIGO criteria [20], GTN was diagnosed as an hCG plateau of \pm 10% over the course of at least 3 weeks (days 1, 7, 14 and 21), or a rise of serum hCG > 10% over the course of 2 weeks (days 1, 7, and 14), or metastasis before hCG plateau or rise.

Statistical analyses were conducted using SPSS statistical software (version 21.0, SPSS Inc., Chicago, IL). The Chi-square test, Fisher's exact test, Student's *t*-test and Mann-Whitney test were used to compare CHM clinical characteristics between NA and SA adolescents. Linear regression analysis was used to assess the relationship between clinical factors and the development of postmolar GTN. Odds Ratio was calculated for a 95% confidence interval. Statistical significance was set at $p < 0.05$.

This study was approved by the Institutional Committees of Human Research Ethics (#2004-P-001372/13) at the Brigham and Women's Hospital, São Paulo State University, Botucatu Medical School (#04648312.0.1001.5411), Maternidad Concepción Palacios de Caracas, and University Hospital of Caracas, Central University of Venezuela (#CBE 26/2011).

3. Results

Of 510 patients diagnosed with hydatidiform mole at the New England Trophoblastic Disease Center (NA), 67 (13.1%) were adolescents, 52 (77.6%) of whom had histopathologic evidence of CHM. Of 955 women diagnosed with hydatidiform mole at the South American centers, 295 (30.9%) were adolescents, 254 (86.1%) of whom had histopathologic findings compatible with CHM. After all cases with missing data were excluded, 45 NA adolescents and 240 SA adolescents with CHM were included in the study (Fig. 1).

Median patient age was 17 years (12–19 years) in SA and 18 years (14–19 years) in NA ($p = 0.189$). Table 1 shows the frequency of CHM clinical complications at admission. Vaginal bleeding (SA = 69%, NA = 51%; $p = 0.020$), anemia (SA = 48%, NA = 18%; $p < 0.001$), and high median serum hCG levels (SA = 232,860 mIU/mL, NA = 136,412 mIU/mL; $p = 0.039$) were more frequent in SA than in NA. Median gestational age at diagnosis (SA = 12 weeks, NA = 11 weeks; $p = 0.030$) differed between groups whereas rate of GTN development after CHM (SA = 20%, NA = 27%; $p = 0.282$) showed no significant difference between SA and NA adolescents.

Linear logistic regression revealed that, compared to NA adolescents, clinical factors associated with risk of post-molar GTN were greater in number and magnitude among SA adolescents (Table 2). Thus, anemia ($p < 0.001$, OR = 3.51, 95% CI = 1.73–7.08), preeclampsia ($p = 0.018$, OR = 3.98, 95% CI = 1.27–12.49), uterine size > gestational age ($p = 0.004$, OR = 2.60, 95% CI = 1.35–5.01), and theca lutein cysts > 6 cm ($p = 0.011$, OR = 3.07, 95% CI = 1.30–7.31) were associated with post-CHM GTN in SA, but not in NA adolescents.

4. Discussion

Our results show that median patient age did not significantly differ between NA and SA adolescents. However, although teen pregnancy rate in the United States is as high as that in developing countries [21], the percentage of adolescents with molar pregnancy found in this study was over two-fold higher in SA than in NA.

CHM rate was similar in both groups investigated, in agreement with several other studies demonstrating that risk of CHM, but not partial mole, is strongly associated with maternal age [1–3]. However, the exact mechanism leading to the increased incidence of molar pregnancy at the extremes of reproductive age remains unknown, especially among young women with CHM [2]. Strong correlations between

Download English Version:

<https://daneshyari.com/en/article/6182990>

Download Persian Version:

<https://daneshyari.com/article/6182990>

[Daneshyari.com](https://daneshyari.com)